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M14th International Congress on Infectious Diseases (ICID) Abs
that clinical care will not be harmed by control measures
such as: de-escalation of therapy, dose optimization, and
parenteral to oral conversion of antimicrobials with excel-
lent bioavailability can decrease the length of hospital stay
and health care costs.
doi:10.1016/j.ijid.2010.02.2185
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Infections caused by multidrug-resistant bacteria con-
tinue to challenge physicians in the daily practice. We
face growing resistance among Gram-positive and Gram-
negative pathogens that cause infection in the hospital
and in the community. Rice recently reported these as
the ‘‘ESKAPE’’ pathogens (Enterococcus faecium, Staphy-
lococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumanii, Pseudomonas aeruginosa, and Enterobacter
species) to emphasize that they currently cause the majority
of world-wide hospital infections and effectively ‘‘escape’’
the effects of antibacterial drugs.
In this context, controlling antibiotic use and bacterial
resistance trough an antibiotic stewardship program (ASP)
is of major importance to all professionals involved in infec-
tious diseases.
A critical need to develop new antimicrobial compounds
and to use the recently approved agents appropriately are
components of all ASP. Unfortunately, most of the agents
which are in the late stage of develop have activity only
against Gram-positives and none is active for treatment of
infections caused by the Gram-negative ESKAPE pathogens.
We have analized the body of the literature with the aim
to deﬁne, within a ASP, the opportunity of use and the poten-
tial advantages of new antibiotics in order to reduce the
emergence and selection of resistant pathogens.
Related with the role of the new antibiotics in a Asp, it is
possible to consider the following points: i-the use of tige-
cycline instead of carbapenems in clinical settings with high
rates of carbapenems-resistant pathogens (ie. in nosocomial
peritonitis), ii-the use of doripenem in extended-infusion
(ie. in severe infections due to Pseudomonas aeruginosa);
iii-the use of daptomycin at high doses (ie. in infections
due to methicillin-resistant Staphylococcus aureus) and iv-
the use of ceftobiprole as empiric monotherapy (ie. in some
suspected mixed infections).
The use of the new antibiotics in the daily practice
based on the individual patient characteristics, causative
organism, site of infection, and pharmacokinetic and phar-
macodynamic characteristics of the drug is an important
part of an ASP.
doi:10.1016/j.ijid.2010.02.2186
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2.001
tate of the Art on ARV Therapy: How Many Standards of
are?
. Cahn
Foundation Huesped, Buenos Aires, Argentina
Albeit nobody would support the idea of ‘‘ﬁrst and second
lass medicine’’, in real life we confront AIDS with at leat
wo standards of care. When to start ARV therapy remains a
atter of debate. No disagreement exists for symptomatic
atients, as well as for asymptomatic individuals with CD4
ounts of 350/ mm3 or below. In resource-poor settings,
HO recommended until late 2009 that adolescents and
dults should start HAART when they have advanced HIV
isease, mildly symptomatic and asymptomatic disease,
HO Stage II or I HIV disease with CD4 counts <200/mm3
These recommendations were updated in November 2009
nd look now closer to those released by other interna-
ional bodies. Some Western countries guidelines panels,
ike the DHHS recommends now treatment initiation in
symptomatic patients when the CD4 count falls below
50/mm3, and have shown a divided opinion regarding the
f treatment should be considered in patients with CD4
ell counts <500/mm3, particularly if the patient has high
iral load, age above 50 and/or comorbidities like HBV or
CV coinfections, among others. Increasing amount of data
uggest that by starting earlier, the so called ‘‘non-AIDS’’
iseases driving to mortality in the HAART era might be dra-
atically reduced. On top of the beneﬁts at the individual
evel, ART has been shown as a prevention tool by reduc-
ng the median viral load at the community level.Currently
vailable co formulations are the best options for ARV back-
one in naive patients. Issues such as childbearing potential
nd baseline resistance need to be taken into consideration
hen selecting a regimen. Controversies remain on whether
o use a PI or an NNRTI as the third drug in initial therapy,
articularly important in the presence of advanced disease.
he bottom line is that one size does not ﬁt for all in this
hallenging ﬁeld.
oi:10.1016/j.ijid.2010.02.2187
2.002
rug Resistance and Other Laboratory Monitoring Assays
n HIV infection
. Hirsch
Harvard Medical School, Boston, MA, USA
Although CD4 cell counts and plasma viral load assays
re the principal laboratory tests used to monitor the
rogress of HIV-1 infections, several other assays are assum-
ng increasing importance to adequately assess the beneﬁts
f antiretroviral therapy (ART) in infected individuals. The
ccessibility of such assays will vary greatly, depending on
he resources available to treat HIV infections.
Where testing capability exists, HIV drug resistance test-
ng is useful when patients enter care prior to initiating
herapy and again when considering change of regimens
